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Background
The immunomodulatory drug (IMiD) lenalidomide has
single-agent activity against RRMM, and synergistic
effects when combined with dexamethasone. Overex-
pression of PD-L1 is associated with tumor invasiveness
in MM cells and may be a mechanism of immune eva-
sion. Pembrolizumab, a highly selective, humanized
IgG4 anti-PD-1 monoclonal antibody designed to block
interaction of PD-1 with PD-L1 and PD-L2, may synergize
with IMiDs to enhance tumor suppression. KEYNOTE-
023 (NCT02036502), an open-label, Phase I, multicenter,
nonrandomized, dose-escalation trial will evaluate the
safety, tolerability, and efficacy of pembrolizumab in com-
bination with lenalidomide and low-dose dexamethasone
in patients with RRMM.
Methods
Patients ≥18 years with RRMM who have failed ≥2 prior
therapies including bortezomib and an IMiD and were
refractory to their last line of treatment are eligible.
Other key eligibility criteria include measurable disease,
ECOG performance status 0/1, and adequate organ
function. Key exclusion criteria include history of
repeated infections, primary amyloidosis, hyperviscosity,
plasma cell leukemia, POEMS syndrome, Waldenström
macroglobulinemia, or IgM myeloma; immunosuppres-
sive disorder; prior anti-PD-1/anti-PD-L1 therapy; allo-
geneic stem cell transplant; or autologous stem cell
transplant ≤12 weeks from first infusion. Using a modi-
fied 3+3 design followed by toxicity probability interval
(TPI) for dose confirmation, cohorts of 3-6 patients per
dose level will be enrolled sequentially at escalating
doses of pembrolizumab 2, 5, or 10 mg/kg Q2W with
low-dose dexamethasone 40 mg and lenalidomide
25 mg until MTD or MAD. Additional patients will
receive pembrolizumab in combination with dexa-
methasone/lenalidomide to confirm the dose based on
the TPI algorithm and to evaluate safety and prelimin-
ary efficacy. Treatment will continue for 24 months or
until complete response, disease progression, or intoler-
able toxicity. Primary objectives are to establish MTD/
MAD and determine safety and tolerability of the com-
binations. Efficacy end points are stringent complete
response, complete response, and very good partial
response rate (sCR+CR+VGPR rate); ORR; time to
response; duration of response; PFS; OS; and correlation
of PD-L1 expression with efficacy. Exploratory objec-
tives are PK and relationship between antitumor activity
and candidate biomarkers. Response is assessed using
International Myeloma Working Group criteria. AEs are
graded per NCI CTCAE v4.0 in all patients receiving ≥1
dose. RP2D will be determined from the dose-response
relationship and other tolerability data. Descriptive statis-
tics will summarize efficacy end points for each dose level.
Recruitment is ongoing.
Trial registration
ClinicalTrials.gov identifier NCT02036502.1Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain
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